Effects of metformin on retinoblastoma growth in vitro and in vivo
- Authors:
- Katarzyna Brodowska
- Sofia Theodoropoulou
- Melissa Meyer Zu Hörste
- Eleftherios I. Paschalis
- Kimio Takeuchi
- Gordon Scott
- David J. Ramsey
- Elizabeth Kiernan
- Mien Hoang
- Joanna Cichy
- Joan W. Miller
- Evangelos S. Gragoudas
- Demetrios G. Vavvas
-
Affiliations: Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA, Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland - Published online on: September 11, 2014 https://doi.org/10.3892/ijo.2014.2650
- Pages: 2311-2324
This article is mentioned in:
Abstract
Broaddus E, Topham A and Singh AD: Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol. 93:21–23. 2009. | |
Rodriguez-Galindo CC, Wilson MWM, Haik BGB, et al: Treatment of metastatic retinoblastoma. Ophthalmology. 110:1237–1240. 2003. View Article : Google Scholar | |
Roarty JD, McLean IW and Zimmerman LE: Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 95:1583–1587. 1988. View Article : Google Scholar : PubMed/NCBI | |
Shaw RJ, Lamia KA, Vasquez D, et al: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI | |
Marr BP, Hung C, Gobin YP, Dunkel IJ, Brodie SE and Abramson DH: Success of intra-arterial chemotherapy (chemo-surgery) for retinoblastoma: effect of orbitovascular anatomy. Arch Ophthalmol. 130:180–185. 2012. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Li M, Song B, et al: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol. 31:264–270. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bianciotto C, Shields CL, Iturralde JC, Sarici A, Jabbour P and Shields JA: Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology. 119:843–849. 2012. View Article : Google Scholar : PubMed/NCBI | |
Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS and Reddy MA: Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology. 119:611–616. 2012. View Article : Google Scholar : PubMed/NCBI | |
Miyano-Kurosaki N, Kurosaki K, Hayashi M, et al: 2-amino-phenoxazine-3-one suppresses the growth of mouse malignant melanoma B16 cells transplanted into C57BL/6Cr Slc mice. Biol Pharm Bull. 29:2197–2201. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ghassemi F and Shields CL: Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 130:1268–1271. 2012. View Article : Google Scholar : PubMed/NCBI | |
Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res. 42:922–933. 2012. View Article : Google Scholar : PubMed/NCBI | |
Munier FL, Gaillard M-C, Balmer A, et al: Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 96:1078–1083. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shields CLC, Honavar SGS, Shields JAJ, Demirci HH, Meadows ATA and Naduvilath TJT: Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol. 120:460–464. 2002. View Article : Google Scholar : PubMed/NCBI | |
Shields CL, Shelil A, Cater J, Meadows AT and Shields JA: Development of new retinoblastomas after 6 cycles of chemo-reduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol. 121:1571–1576. 2003. View Article : Google Scholar : PubMed/NCBI | |
Sussman DA, Escalona-Benz E, Benz MS, et al: Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Arch Ophthalmol. 121:979–984. 2003. View Article : Google Scholar : PubMed/NCBI | |
Schefler AC, Cicciarelli N, Feuer W, Toledano S and Murray TG: Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Opthalmology. 114:162–169. 2007. View Article : Google Scholar | |
Shields CL: Forget-me-nots in the care of children with retinoblastoma. Semin Ophthalmol. 23:324–334. 2009. View Article : Google Scholar : PubMed/NCBI | |
Shields CL, Palamar M, Sharma P, et al: Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch Ophthalmol. 127:282–290. 2009. View Article : Google Scholar : PubMed/NCBI | |
Benz MS, Scott IU, Murray TG, Kramer D and Toledano S: Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 118:577–578. 2000.PubMed/NCBI | |
Nishimura S, Sato T, Ueda H and Ueda K: Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol. 19:4182–4183. 2001.PubMed/NCBI | |
Stumvoll M, Nurjhan N, Perriello G, Dailey G and Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 333:550–554. 1995. View Article : Google Scholar : PubMed/NCBI | |
Zhou G, Myers R, Li Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI | |
Hundal HS, Ramlal T, Reyes R, Leiter LA and Klip A: Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology. 131:1165–1173. 1992. | |
Sahra IB, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008. View Article : Google Scholar : PubMed/NCBI | |
Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007. View Article : Google Scholar | |
Cufi S, Corominas-Faja B, Vazquez-Martin A, et al: Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 3:395–398. 2012.PubMed/NCBI | |
Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2:e1992011. View Article : Google Scholar : PubMed/NCBI | |
Kato K, Gong J, Iwama H, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560. 2012. View Article : Google Scholar : PubMed/NCBI | |
Martin MJ, Hayward R, Viros A and Marais R: Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2:344–355. 2012. View Article : Google Scholar : PubMed/NCBI | |
Phoenix KN, Vumbaca F and Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 113:101–111. 2009. View Article : Google Scholar | |
Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI | |
Zhuang Y and Miskimins WK: Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, down-regulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 3:182008. View Article : Google Scholar : PubMed/NCBI | |
Towler MC and Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 100:328–341. 2007. View Article : Google Scholar : PubMed/NCBI | |
Vijg J and Campisi J: Puzzles, promises and a cure for ageing. Nature. 454:1065–1071. 2008. View Article : Google Scholar : PubMed/NCBI | |
Moruno-Manchón JF, Pérez-Jiménez E and Knecht E: Glucose induces autophagy under starvation conditions by a p38 MAPK-dependent pathway. Biochem J. 449:497–506. 2013.PubMed/NCBI | |
Hardie DG: The LKB1-AMPK pathway-friend or foe in cancer? Cancer Cell. 23:131–142. 2013. View Article : Google Scholar : PubMed/NCBI | |
Doyle A, Zhang G, Abdel Fattah EA, Eissa NT and Li YP: Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J. 25:99–110. 2011. View Article : Google Scholar | |
Matsuzawa T, Kim B-H, Shenoy AR, Kamitani S, Miyake M and Macmicking JD: IFN-γ elicits macrophage autophagy via the p38 MAPK signaling pathway. J Immunol. 189:813–818. 2012. | |
Webber JL and Tooze SA: Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and p38IP. EMBO J. 29:27–40. 2010. View Article : Google Scholar : PubMed/NCBI | |
Thyagarajan A, Jedinak A, Nguyen H, et al: Triterpenes from Ganoderma Lucidum induce autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase (p38 MAPK). Nutr Cancer. 62:630–640. 2010. View Article : Google Scholar : PubMed/NCBI | |
Osborne CK, Bolan G, Monaco ME and Lippman ME: Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA. 73:4536–4540. 1976. View Article : Google Scholar : PubMed/NCBI | |
Metformin insert 1–6, 2009. Distributed by: Bristol-Myers Squibb Company; Princeton, NJ 08543, USA: http://packagein-serts.bms.com/pi/pi_glucophage_xr.pdf. | |
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ and Dennis PA: Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metabol. 24:469–480. 2013. View Article : Google Scholar : PubMed/NCBI | |
Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, et al: In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol. 668:373–382. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hadad SM, Appleyard V and Thompson AM: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 114:391–399. 2009. | |
Dool CJ, Mashhedi H, Zakikhani M, et al: IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocr Relat Cancer. 18:699–709. 2011. View Article : Google Scholar | |
Wilcock C and Bailey CJ: Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 24:49–57. 1994. View Article : Google Scholar : PubMed/NCBI | |
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI | |
Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A and Decensi A: Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 18:701–705. 2009. View Article : Google Scholar : PubMed/NCBI | |
Noto H, Goto A, Tsujimoto T and Noda M: Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 7:e334112012. View Article : Google Scholar : PubMed/NCBI | |
Becker C, Meier CR, Jick SS and Bodmer M: Case-control analysis on metformin and cancer of the esophagus. Cancer Causes Control. 24:1763–1770. 2013. View Article : Google Scholar : PubMed/NCBI | |
Becker C, Jick SS, Meier CR and Bodmer M: Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol Oncol. 129:565–569. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bodmer M, Becker C, Jick SS and Meier CR: Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer. 78:133–137. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 21:280–286. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE and Bergstralh EJ: Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol. 32:43.e1–7. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol. 107:620–626. 2012. View Article : Google Scholar : PubMed/NCBI | |
Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A and Sasidhar M: The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 12:4102012. View Article : Google Scholar : PubMed/NCBI | |
Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 123:200–204. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bodmer M, Meier C, Krähenbühl S, Jick SS and Meier CR: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 33:1304–1308. 2010. View Article : Google Scholar : PubMed/NCBI | |
Tomimoto A, Endo H, Sugiyama M, et al: Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Science. 99:2136–2141. 2008. View Article : Google Scholar : PubMed/NCBI | |
Theodoropoulou S, Kolovou PE, Morizane Y, et al: Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J. 24:2620–2630. 2010. View Article : Google Scholar | |
Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 280:39582–39593. 2005. View Article : Google Scholar : PubMed/NCBI | |
Inoki KK, Zhu TT and Guan K-LK: TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115:577–590. 2003. View Article : Google Scholar : PubMed/NCBI | |
Cheng SWY, Fryer LGD, Carling D and Shepherd PR: Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem. 279:15719–15722. 2004. View Article : Google Scholar : PubMed/NCBI | |
Sarbassov DD, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol. 17:596–603. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI | |
Hawley SA, Gadalla AE, Olsen GS and Hardie DG: The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 51:2420–2425. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kalender A, Selvaraj A, Kim SY, et al: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI | |
Liu B, Fan Z, Edgerton SM, et al: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI | |
Li C, Liu VWS, Chan DW, Yao KM and Ngan HYS: LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer. 22:15–22. 2012. View Article : Google Scholar : PubMed/NCBI | |
Capano M and Crompton M: Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem J. 395:57–64. 2006. View Article : Google Scholar : PubMed/NCBI | |
Xi X, Han J and Zhang JZ: Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem. 276:41029–41034. 2001. View Article : Google Scholar : PubMed/NCBI | |
Würth R, Pattarozzi A, Gatti M, et al: Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle. 12:145–156. 2013.PubMed/NCBI | |
Bao B, Wang Z, Ali S, et al: Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevent Res. 5:355–364. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ben Sahra I, Regazzetti C, Robert G, et al: Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71:4366–4372. 2011.PubMed/NCBI | |
Soranna D, Scotti L, Zambon A, et al: Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 17:813–822. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bost F, Sahra IB, Le Marchand-Brustel Y and Tanti JF: Metformin and cancer therapy. Curr Opin Oncol. 24:103–108. 2012. View Article : Google Scholar | |
Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI | |
Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 9:1057–1064. 2010. View Article : Google Scholar : PubMed/NCBI |